Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.099,96
-0,59%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Sonnet BioTherapeutics Holdings Inc (SONN) Sonnet BioTherapeutics Holdings Inc (SONN) Notizie

Sonnet BioTherapeutics Holdings Inc

SONN
1,42
-0,02 (-1,39%)
24 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
23/12/202422:05EDGAR2Form D - Notice of Exempt Offering of Securities
23/12/202415:20GLOBESonnet BioTherapeutics Announces Release of the Next CEO..
17/12/202415:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
17/12/202414:50EDGAR2Form 8-K - Current report
17/12/202414:50GLOBESonnet BioTherapeutics Reports Fiscal Year 2024 Financial..
10/12/202415:25EDGAR2Form 8-K - Current report
10/12/202415:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/12/202421:42GLOBESonnet BioTherapeutics Announces $3.9 Million Registered..
09/12/202414:50EDGAR2Form 8-K - Current report
09/12/202414:45GLOBESonnet BioTherapeutics Announces Topline Safety Data..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/12/202403:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202415:20EDGAR2Form 8-K - Current report
04/12/202415:20GLOBESonnet BioTherapeutics Announces Publication Detailing the..
26/11/202423:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
12/11/202415:15GLOBESonnet BioTherapeutics Releases Virtual Investor ‘”What this..
08/11/202414:30EDGAR2Form 8-K - Current report
07/11/202415:22EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
06/11/202419:20GLOBESonnet BioTherapeutics Announces Pricing of $5.0 Million..
06/11/202415:22EDGAR2Form S-1/A - General form for registration of securities..
06/11/202414:48EDGAR2Form 8-K - Current report
06/11/202414:30GLOBESonnet BioTherapeutics Announces Issuance of U.S. Patent..
04/11/202415:01EDGAR2Form S-1/A - General form for registration of securities..
28/10/202414:01EDGAR2Form S-1 - General form for registration of securities under..
17/10/202414:50EDGAR2Form 8-K - Current report
17/10/202414:45GLOBESonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
09/10/202414:56EDGAR2Form 8-K - Current report
09/10/202414:45GLOBESonnet BioTherapeutics Inc. Enters into Licensing Agreement..
04/10/202414:30GLOBESonnet BioTherapeutics to Receive Non-Dilutive Funding..
30/9/202415:00GLOBESonnet BioTherapeutics Announces Launch of CEO Corner..
30/9/202414:30EDGAR2Form 8-K - Current report
25/9/202414:30GLOBESonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
18/9/202414:36EDGAR2Form 8-K - Current report
18/9/202414:30GLOBESonnet BioTherapeutics Completes Enrollment in Phase 1 Study..
12/9/202423:15EDGAR2Form 8-K - Current report
09/9/202422:08EDGAR2Form 8-K - Current report
04/9/202415:15GLOBESonnet BioTherapeutics to Participate in the Virtual..
30/8/202414:30EDGAR2Form 8-K - Current report
19/8/202423:27EDGAR2Form DEF 14A - Other definitive proxy statements
19/8/202414:50EDGAR2Form 8-K - Current report
19/8/202414:45GLOBESonnet BioTherapeutics Enters into Clinical Collaboration..
14/8/202414:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202414:41EDGAR2Form 8-K - Current report
Apertura: 1,43 Min: 1,41 Max: 1,50
Chiusura: 1,44

La tua Cronologia

NASDAQ
SONN
Sonnet BioTherapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network